株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

神経保護剤:治療用途および世界市場

Neuroprotective Agents: Therapeutic Applications and Global Markets

発行 BCC Research 商品コード 648089
出版日 ページ情報 英文 133 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.05円で換算しております。
Back to Top
神経保護剤:治療用途および世界市場 Neuroprotective Agents: Therapeutic Applications and Global Markets
出版日: 2018年06月05日 ページ情報: 英文 133 Pages
概要

世界の神経保護剤市場規模は、2017年から2022年にかけての予測期間中に6.8%のCAGR (年間複合成長率) で推移し、2017年の544億米ドルから、2022年までに758億米ドルの規模に成長すると予測されています。

当レポートでは、世界の神経保護剤市場を調査し、市場の概要、市場および技術の背景、治療指標技術タイプ・治療指標・地域など各種区分別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場・技術背景

  • 神経保護
    • 神経保護治療が必要とされる理由は?
    • 神経保護戦略
  • 脳血管疾患
    • 脳卒中
    • 脳卒中における神経保護
  • 神経変性疾患
    • パーキンソン病
    • ALS (筋萎縮性側索硬化症)
    • 多発性硬化症
    • アルツハイマー病
    • ハンチントン病
    • 脊髄性筋萎縮症 (SMA)
    • てんかん
    • 神経変性疾患における神経保護
  • 眼疾患
    • 緑内障
    • 非動脈炎性前部虚血性視神経症 (NAION)
    • 加齢黄斑編変性 (AMD)
    • 糖尿病性網膜症
    • 眼疾患における神経保護
  • 外傷性CNS (中枢神経系) 損傷
    • 外傷性脳損傷
    • 外傷性脊髄損傷
    • 外傷性CNS (中枢神経系) 損傷における神経保護

第4章 市場分析:技術タイプ別

  • 治療薬
  • 再生医療製品

第5章 市場分析:治療指標別

  • 心血管疾患
  • 神経変性疾患
  • 眼疾患
  • 外傷性CNS (中枢神経系) 損傷

第6章 市場分析:地域別

第7章 企業プロファイル

BCC Researchについて

目次
Product Code: PHM188A

Report Highlights

The global market for neuroprotective agents will grow from $54.4 billion in 2017 to $75.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.8% for the period of 2017-2022.

Report Includes:

  • 39 tables
  • An overview of the global market for neuroprotective agents and their therapeutic applications
  • Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Market breakdowns by indication, mechanism of action, and by region
  • Introduction of breakthrough biomarker studies that assist in neuroprotection
  • Discussion of various neurodegenarative disorders
  • Profiles of key companies in the market, including Bayer Healthcare, Eisai Inc., Glaxosmithkline Plc, Merck Serono S.A., Novartis Ag and Teva Pharmaceutical Industries Ltd.

Report Scope

The scope of this report covers the global market for small molecule drugs, monoclonal antibodies, gene and cell therapies, and other biotechnology products that are approved or being developed for the treatment of neurological disorders.

Therapeutic indications are grouped under four categories: cerebrovascular diseases, neurodegenerative disorders, ophthalmic diseases and traumatic CNS injuries. Indication subcategories include stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, spinal muscular atrophy, epilepsy, glaucoma, age-related macular degeneration, optic neuropathies, diabetic retinopathy and traumatic brain and spinal cord injuries. The report does not cover the neuroprotective agents that are used for protecting the brain during risky neurosurgeries and other general operations.

Analyst Credentials

Ufuk Ezer. Ezer holds a bachelor's degree in bioengineering and a master's degree in biotechnology, bioprocessing and business management. He possesses extensive pharmaceutical research and development experience and has participated in projects for various international institutions and organizations. Ezer has been granted scholarships and awards during his post-study works in countries such as Japan and Panama based on the high quality of his work and excellence in the fields of research.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Neuroprotection
    • Why Are Neuroprotective Therapies Needed?
    • Neuroprotective Strategies
  • Cerebrovascular Disease
    • Stroke
    • Neuroprotection in Stroke
  • Neurodegenerative Disorders
    • Parkinson's Disease
    • Amyotrophic Lateral Sclerosis
    • Multiple Sclerosis
    • Alzheimer's Disease
    • Huntington's Disease
    • Spinal Muscular Atrophy
    • Epilepsy
    • Neuroprotection in Neurodegenerative Disorders
  • Ophthalmic Diseases
    • Glaucoma
    • Nonarteritic Anterior Ischemic Optic Neuropathy
    • Age-related Macular Degeneration
    • Diabetic Retinopathy
    • Neuroprotection in Ophthalmic Diseases
  • Traumatic CNS Injuries
    • Traumatic Brain Injury
    • Traumatic Spinal Cord Injuries
    • Neuroprotection in Traumatic CNS Injuries

Chapter 4: Market Breakdown by Technology Type

  • Therapeutic Agents
    • Antisense Agents
    • Anti-amyloid Agents
    • Immune Response Modifiers
    • Antioxidants
    • Anti-angiogenic Agents
    • Anti-Parkinson's Agents
    • Anticonvulsants
    • Ocular Hypotensives
    • Thrombolytics
    • Blood Thinning Agents
    • Anti-dementia Agents
    • Other Neuroprotective Agents
  • Regenerative Medicine Products
    • Brainstorm Cell Therapeutics' Nurown as First ALS Cell Therapy in the U.S.
    • Neuronata-R to Expand to International ALS Markets
    • Multistem Fast-tracked for Ischemic Stroke
    • CEVA101 Advances in Traumatic Brain Injury Trials
    • Asterias Biotherapeutics Snatches RMAT for Spinal Cord Injuries
    • CTX0E03 Advances in PISCES II Trials for Stroke Disability

Chapter 5: Market Breakdown by Therapeutic Indication

  • Neuroprotective Agents for Cerebrovascular Disease
  • Neuroprotective Agents for Neurodegenerative Disorders
  • Neuroprotective Agents for Ophthalmic Diseases
  • Neuroprotective Agents for Traumatic Central Nervous System Injuries

Chapter 6: Market Breakdown by Region

Chapter 7: Company Profiles

About BCC Research

  • About BCC Research
  • BCC Library Access
  • BCC Custom Research

List of Tables

  • Summary Table: Global Market for Neuroprotective Agents, by Region, Through 2022 ($ Millions)
    • Table 1: Global Market for Neuroprotective Agents, by Technology Type, Through 2022 ($ Millions)
    • Table 2: Global Market for Neuroprotective Agents, by Application, Through 2022 ($ Millions)
    • Table 3: Global Market for Therapeutic Agents, by Drug Class, Through 2022 ($ Millions)
    • Table 4: Global Market for Antisense Agents, Through 2022 ($ Millions)
    • Table 5: Global Market for Anti-Amyloid Agents, Through 2022 ($ Millions)
    • Table 6: Neuroprotective Interferons Available in Global Markets, by Brand
    • Table 7: Neuroprotective Monoclonal Antibodies Available in Global Markets, by Brand
    • Table 8: Key Immune Response Modifiers in Clinical Development
    • Table 9: Global Market for Immune Response Modifiers, Through 2022 ($ Millions)
    • Table 10: Key Antioxidants in Clinical Development
    • Table 11: Global Market for Antioxidants, Through 2022 ($ Millions)
    • Table 12: Key Anti-angiogenic Agents in Clinical Development
    • Table 13: Global Market for Anti-Angiogenic Agents, Through 2022 ($ Millions)
    • Table 14: Global Market for Anti-Parkinson's Agents, Through 2022 ($ Millions)
    • Table 15: Key Anticonvulsants in Clinical Development
    • Table 16: Global Market for Anticonvulsants, Through 2022 ($ Millions)
    • Table 17: Global Market for Ocular Hypotensives, Through 2022 ($ Millions)
    • Table 18: Global Market for Thrombolytics, Through 2022 ($ Millions)
    • Table 19: Global Market for Blood Thinning Agents, Through 2022 ($ Millions)
    • Table 20: Global Market for Anti-Dementia Agents, Through 2022 ($ Millions)
    • Table 21: Key Neuroprotective Drug Candidates with Novel MoA in Clinical Development
    • Table 22: Global Market for Other Neuroprotective Agents, Through 2022 ($ Millions)
    • Table 23: Global Market for Regenerative Medicine Products, Through 2022 ($ Millions)
    • Table 24: Global Market Share for Key Players in Neuroprotection, 2017 (%)
    • Table 25: Global Market for Neuroprotective Agents, by Therapeutic Indication, Through 2022 ($ Millions)
    • Table 26: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, Through 2022 ($ Millions)
    • Table 27: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, Type, Through 2022 ($ Millions)
    • Table 28: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Type, Through 2022 ($ Millions)
    • Table 29: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Type, Through 2022 ($ Millions)
    • Table 30: Global Market for Neuroprotective Agents, by Region, Through 2022 ($ Millions)
    • Table 31: North American Market for Neuroprotective Agents, by Indication, Through 2022 ($ Millions)
    • Table 32: European Market for Neuroprotective Agents, by Indication, Through 2022 ($ Millions)
    • Table 33: Asia-Pacific Market for Neuroprotective Agents, by Indication, Through 2022 ($ Millions)
    • Table 34: ROW Market for Neuroprotective Agents, by Indication, Through 2022 ($ Millions)
    • Table 35: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, by Region, Through 2022 ($ Millions)
    • Table 36: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, Region, Through 2022 ($ Millions)
    • Table 37: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Region, Through 2022 ($ Millions)
    • Table 38: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Region, Through 2022 ($ Millions)

List of Figures

  • Summary Figure: Global Market for Neuroprotective Agents, by Region, 2016-2022 ($ Millions)
    • Figure 1: Global Market for Neuroprotective Agents, by Technology Type, 2016-2022 ($ Millions)
    • Figure 2: Global Market for Neuroprotective Agents, by Application, 2016-2022 ($ Millions)
    • Figure 3: Global Market for Therapeutic Agents, by Drug Class, 2016-2022 ($ Millions)
    • Figure 4: Global Market for Antisense Agents, 2016-2022 ($ Millions)
    • Figure 5: Global Market for Anti-Amyloid Agents, 2016-2022 ($ Millions)
    • Figure 6: Global Market for Immune Response Modifiers, 2016-2022 ($ Millions)
    • Figure 7: Global Market for Antioxidants, 2016-2022 ($ Millions)
    • Figure 8: Global Market for Anti-Angiogenic Agents, 2016-2022 ($ Millions)
    • Figure 9: Global Market for Anti-Parkinson's Agents, 2016-2022 ($ Millions)
    • Figure 10: Global Market for Anticonvulsants, 2016-2022 ($ Millions)
    • Figure 11: Global Market for Ocular Hypotensives, 2016-2022 ($ Millions)
    • Figure 12: Global Market for Thrombolytics, 2016-2022 ($ Millions)
    • Figure 13: Global Market for Blood Thinning Agents, 2016-2022 ($ Millions)
    • Figure 14: Global Market for Anti-Dementia Agents, 2016-2022 ($ Millions)
    • Figure 15: Global Market for Other Neuroprotective Agents, 2016-2022 ($ Millions)
    • Figure 16: Global Market for Regenerative Medicine Products, 2016-2022 ($ Millions)
    • Figure 17: Global Market Share for Key Players in Neuroprotection, 2017 (%)
    • Figure 18: Global Market for Neuroprotective Agents, by Therapeutic Indication, 2016-2022 ($ Millions)
    • Figure 19: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, 2016- 2022 ($ Millions)
    • Figure 20: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Type, 2017-2022 ($ Millions)
    • Figure 21: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Type, 2016-2022 ($ Millions)
    • Figure 22: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Type, 2016-2022 ($ Millions)
    • Figure 23: Global Market for Neuroprotective Agents, by Region, 2016-2022 ($ Millions)
    • Figure 24: North American Market for Neuroprotective Agents, by Indication, 2016-2022 ($ Millions)
    • Figure 25: European Market for Neuroprotective Agents, by Indication, 2016-2022 ($ Millions)
    • Figure 26: Asia-Pacific Market for Neuroprotective Agents, by Indication, 2016-2022 ($ Millions)
    • Figure 27: ROW Market for Neuroprotective Agents, by Indication, 2016-2022 ($ Millions)
    • Figure 28: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, by Region, 2016-2022 ($ Millions)
    • Figure 29: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Region, 2016-2022 ($ Millions)
    • Figure 30: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Region, 2016-2022 ($ Millions)
    • Figure 31: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Region, 2016-2022 ($ Millions)
Back to Top